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Abstract
Background: Splenic metastases occur in rare cases with a few case reports of patients in the
literature. Generally, splenic metastases mean late dissemination of a disease. Solitary splenic
metastases from solid tumors are extremely unusual.
Case presentation: We report a case of a patient with ovarian mucinous cystadenocarcinoma
who underwent splenectomy for isolated parenchymal metastasis.
Conclusion:  Ovarian epithelial tumors comprised most of isolated splenic metastases from
gynecologic tumor. When isolated splenic recurrence is suspected on image studies and serum
tumor markers, intraabdominal gross findings should be examined to exclude peritoneal
carcinomatosis. If only spleen was under suspicion of recurrence of ovarian cancer, splenectomy
may play a therapeutic role.
Background
Splenic metastases from solid tumors occur in late stage of
a disease, so those can hardly be an indication for a sur-
gery. Cancers of the ovaries, lung, breast, stomach, skin
and colon are known to metastasize to the spleen [1].
Even though recent reports suggest increasing incidence of
splenic metastasis from gynecologic tumors [2-8], the
number of the cases that isolated splenic metastasis is
fewer than 25 in the literature worldwide. Among them,
solitary parenchymal metastasis would comprise the
small portion. Fewer than 15 cases of splenic metastasis
occur from the ovaries as a primary site, pathology
revealed cystadenocarcinoma.
We present a case of mucinous cystadenocarcinoma that
recurred in the splenic parenchyma.
Case presentation
A 29-year-old woman was admitted our hospital on
August 1999, had been diagnosed as mucinous tumor of
borderline malignancy a year ago. She was followed up at
a local clinic. On the follow-up study, the patient's CEA
level was raised to 43.32 U/L and CT scan showed
splenomegaly with cystic lesion. Her past medical history
was not significant. She already underwent two surgeries.
The first surgery, right salpingo-oophorectomy, was per-
formed at the age of 22 after being diagnosed as dermoid
cyst. She was healthy thereafter. Seven years later, left
ovarian mass was found on the routine check. At the sec-
ond surgery, left ovarian mass excision, mucinous tumor
of borderline malignancy was diagnosed.
During follow-up after the second surgery, she was
referred to our hospital on the suspicion of carcinomato-
sis peritonei. On the preoperative evaluation (Figure 1),
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splenic lesion, which had been existed for 2 years, was
merely noticed as simple cystic lesion unrelated to the
ovarian mass.
To exclude peritoneal carcinomatosis, open laparotomy
was perfomed. On opening the abdomen, no abnormal
gross findings were found except the splenic lesion, which
reported as probable metastatic adenocarcinoma on fro-
zen sections. After splenectomy was carried out, perito-
neal washings and multiple biopsies on the omentum,
peritoneum, mesentery, and left ovary were performed to
rule out possible microscopic peritoneal dissemination.
Suspecting the transabdominal metastasis, 100 mg of cis-
platin was infused into the peritoneal cavity at the end of
the operation; however no intraperitoneal recurrence was
confirmed after tissue diagnosis.
Final pathologic examination (Figure 2) showed meta-
static mucinous cystadenocarcinoma. Peritoneal wash-
ings and multiple biopsies were all negative. The patient
was recovered from the surgery without the evidence of
sepsis of severe thrombocytosis. The patient received 5
courses of Taxol and Carboplatin as postoperative
chemotherapy.
Two years after the surgery, 3 × 3-sized mass on the left
ovary, which assumed to be recurrence, was detected. She
has been followed up at outpatient department receiving
symptomatic treatment and chemotherapy.
Discussion
The frequency of splenic metastasis has been reported 2.3
to 7.1 per cent from autopsy series of cancer patients [9-
11]. Splenic metastases from the ovaries, uterus, uterine
cervix, lung, breast, stomach, skin and colon have been
reported, and ovarian cancer comprises the three fourth.
Until now, in the literature, splenic capsular metastasis
has been reported to occur in the case of far advanced
stage of a disease or in the case of more than one organ
Abdomen CT shows 9 × 8 cm-sized multiseptated cystic lesion with inner calcification in the spleen Figure 1
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was already involved in terminal stage and especially in
the case of peritoneal metastasis. When one or more organ
in the thoracic cavity and abdominal cavity was involved,
the rate of splenic metastasis was 43% [12]. But isolated
splenic metastasis is rare; only fewer than 25 cases were
reported. Some reported hematogenous metastasis to the
parenchyma of the spleen [13]. This mean the spleen is
the organ of the privilege [11,14,15]. It could be explained
by hypothesis of the role of the splenic capsule as physical
barrier; the lack of afferent lymphatics in the splenic
parenchyma, the acute angle of the origin and the tortuos-
ity of the splenic artery, the rhythmic contractile proper-
ties of the spleen, and the immune competence and
possible antineoplastic nature of the splenic tissue itself
[13]. In this case, solitary splenic parenchymal metastasis
from ovarian epithelial tumor was made hematogenously
without intraabdominal dissemination.
Among cases of the isolated splenic metastasis, the ovar-
ian cancers make up the most. After Minazawa et al [16]
firstly performed splenectomy in the splenic metastasis of
ovarian cancer patient, splenectomy, as a therapeutic
modality of splenic metastasis, was supported by similar
articles and studies [17,18]. Recently, splenectomy was
often included in the cytoreductive surgery of the ovarian
cancer [2,3,19].
CT scanning and measurement of serum tumor markers,
especially CA 125, are helpful for detecting the recurrence
and the infrequent splenic metastasis.
We proposed that splenectomy be a proper therapeutic
modality for an isolated splenic metastasis, especially
parenchymal metastasis, from an ovarian cancer. When
isolated splenic recurrence is suspected on the CT
The section reveals papillary hyperplasia of mucinous lining epithelium with stratification and atypism (H&E stain, ×250) Figure 2
The section reveals papillary hyperplasia of mucinous lining epithelium with stratification and atypism (H&E stain, ×250).Publish with BioMed Central    and   every 
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scanning and serum tumor markers, intraabdominal gross
findings should be examined meticulously. If only spleen
was under suspicion of recurrence, splenectomy would be
a proper therapeutic procedure.
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